Key facts
- This page summarizes Seth A. Tasker's Form 4 filing for INFINITY PHARMACEUTICALS, INC..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Jan 2022, 16:00.
Seth A. Tasker - 11 Jan 2022 Form 4 Insider Report for INFINITY PHARMACEUTICALS, INC.
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- N/A
- Reported as of
- 11 Jan 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/Seth A. Tasker
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Seth A. Tasker filed Form 4 for INFINITY PHARMACEUTICALS, INC. on 12 Jan 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INFI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +225,000
- Change %
- Price
- $0.000000
- Shares after
- 225,000
- Date
- 11 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 225,000
- Exercise price
- $1.53
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests as to 1/48th of the shares on January 31, 2022 and vests as to 1/48th of the shares at the end of each calendar month thereafter.